Company-reported prevalence
Bezuclastinib
Overview
| Field | Value |
|---|---|
| Drug | Bezuclastinib |
| Indication | Nonadvanced systemic mastocytosis |
| Disease | Nonadvanced systemic mastocytosis (Non-AdvSM); systemic mastocytosis (SM) as a whole |
| Company | Cogent Biosciences, Inc.; no partner holding rights to bezuclastinib was identified |
| Documents searched | Corporate website, bezuclastinib, pipeline, systemic mastocytosis, and patients and families pages (accessed October 2026); press releases naming bezuclastinib, October 2023 to September 2026; Form 10-K for 2025 (February 2026); Form 10-K for 2024 (February 2025); Form 10-K for 2023 (February 2024); Form 10-Q for the second quarter of 2026 (August 2026); prospectus supplements (November 2025); corporate presentation (September 2026); Summit full results presentation (December 2025); Summit top-line results presentation (July 2025); Summit Part 1b presentation (February 2024) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Prevalence (all systemic mastocytosis): Cogent Biosciences Form 10-K for 2024, February 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Prevalence: Cogent Biosciences Form 10-K for 2024, February 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
No evidence found.
Other countries and regions
No evidence found.
Geography not stated
No evidence found.
Sources the company cites
No evidence found.